it is opposite Rebecca. The early approval process is only for rare diseases as defined by less than 200,000 in the US. What I remember is it is important to have treated enough patients for reliable safety data. Sometimes they require a post approval P3. There is even a possibility of approval right out of phase 2. if the results of 201 are spectacular.
What to hopefully look forward too, page-23
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(25.0%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $32.63K | 10.83M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 28 | 21801548 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 130971725 | 28 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| ATH (ASX) Chart |